Drug Trial Radar · NCT03850873
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 20, 2019
Primary completion
Sep 23, 2021
Study completion Sep 23, 2021
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will be given to people.TQB3616 is taken by mouth daily.
Conditions
- Advanced Breast Cancer
Interventions
TQB3616Drug
TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m,40mg,60mg,80mg,100mg,120mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: Baseline up to 28 days
- MTDTime frame: Baseline up to 28 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
The Fourth Hospital of Hebei Medical University and Hebei
Shijiazhuang, Hebei, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.